Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
NEMinerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. (NERV)

NASDAQ Global Market · Currency in USD
$2.30 ▼ -0.10 (-4.17%)
At close: Oct 23, 4:00 PM ET. Market closed.
$2.33 ▲ +0.03 (+1.30%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$2.40
Open
$2.34
Day's Range
$2.28 – $2.36
52 Week Range
$2.24 – $8.80
Volume
137,586
Avg. Volume
225,465
Market Cap
$109.82M
Beta (5Y Monthly)
-0.12
PE Ratio (TTM)
--
EPS (TTM)
-$8.46
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$10.00

Profile: Minerva Neurosciences, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
7
CEO
Remy Luthringer

Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$0.14
DateEst.Actual
Aug 7, 2026-$0.19-$0.14Beat
May 5, 2026-$0.13-$2.86Miss
Mar 11, 2026-$0.11-$0.64Miss
Nov 5, 2025-$0.35-$0.36Miss
Aug 14, 2025-$0.95-$0.43Beat
May 13, 2025-$1.07-$0.50Beat

Analyst view

Consensus price target
$10.00 ▲ +334.8%
Range $10.00 – $10.00
Rating: Buy
Buy 71% · Hold 29% · Sell 0%

Get free alerts on NERV and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.